Trachoma: transmission, infection, and control

Lancet Infectious Diseases

Volumn 7, Issue 6, 2007, Pages 420-427

  Gambhir, Manoj ^a   Basáñez, María Gloria ^a   Turner, Felicity ^b   Kumaresan, Jacob ^b   Grassly, Nicholas C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b International Trachoma Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ANTIBIOTIC THERAPY; BLINDNESS; CHLAMYDIA TRACHOMATIS; CLINICAL FEATURE; CONJUNCTIVITIS; DISEASE CONTROL; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFECT; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; MATHEMATICAL MODEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REINFECTION; REVIEW; TRACHOMA;

ANTI-BACTERIAL AGENTS; BLINDNESS; CHLAMYDIA TRACHOMATIS; DISEASE PROGRESSION; HUMANS; HYGIENE; MODELS, STATISTICAL; NATIONAL HEALTH PROGRAMS; TRACHOMA; WORLD HEALTH;

EID: 34248579545     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(07)70137-8     Document Type: Review

References (67)

1. Resnikoff S., Pascolini D., Etya'ale D., et al. Global data on visual impairment in the year 2002. Bull World Health Organ 82 (2004) 844-851
2. Molyneux D., Hotez P., and Fenwick A. "Rapid-Impact Interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2 (2005) e336
3. West S., Muñoz B., Mkocha H., et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 366 (2005) 1296-1300
4. Burton M., Holland M., Makalo P., et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet 365 (2005) 1321-1328
5. Wright H., and Taylor H. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us?. Lancet Infect Dis 5 (2005) 313-320
6. West S., Muñoz B., Mkocha H., Hsieh Y., and Lynch M. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol 8 (2001) 137-144
7. Morrison RP. Chlamydial immunology and vaccinology. Proceedings of the Chlamydia Vaccine Development Colloquium; June 3-5, 2003; Alexandria, VA: 19-23.
8. Caldwell H., Wood H., Crane D., et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest 111 (2003) 1757-1769
9. Brunham R., and Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 5 (2005) 149-161
10. Debattista J., Timms P., and Allan J. Immunopathogenesis of Chlamydia trachomatis infections in women. Fertil Steril 79 (2003) 1273-1287
11. Bailey R., Duong T., Carpenter R., Whittle H., and Mabey D. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect 123 (1999) 479-486
12. Ramsey K., Poulsen C., and Motiu P. The in vitro antimicrobial capacity of human colostrum against Chlamydia trachomatis. J Reprod Immunol 38 (1998) 155-167
13. Ghaem-Maghami S., Bailey R., Mabey D., et al. Characterization of B-cell responses to Chlamydia trachomatis antigens in humans with trachoma. Infect Immun 65 (1997) 4958-4964
14. Bowman R., Jatta B., Cham B., et al. Natural history of trachomatous scarring in The Gambia: results of a 12-year longitudinal follow-up. Ophthalmology 108 (2001) 2219-2224
15. West S., Muñoz B., Lynch M., Kayongoya A., Mmbaga B., and Taylor H. Risk factors for constant, severe trachoma among preschool children in Kongwa, Tanzania. Am J Epidemiol 143 (1996) 73-78
16. Grayston J., and Wang S. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis 5 (1978) 73-77
17. Hessel T., Dhital S., Plank R., and Dean D. Immune response to chlamydial 60-kilodalton heat shock protein in tears from Nepali trachoma patients. Infect Immun 69 (2001) 4996-5000
18. Zhang D., Yang X., Shen C., and Brunham R. Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain. Immunology 96 (1999) 314-321
19. Taylor H., Johnson S., Schachter J., Caldwell H., and Prendergast R. Pathogenesis of trachoma: the stimulus for inflammation. J Immunol 138 (1987) 3023-3027
20. Taylor H., Johnson S., Prendergast R., Schachter J., Dawson C., and Silverstein A. An animal model of trachoma II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci 23 (1982) 507-515
21. Grayston J., Wang S., Yeh L., and Kuo C. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 7 (1985) 717-725
22. Detels R., Alexander E., and Dhir S. Trachoma in Punjabi Indians in British Columbia: a prevalence study with comparisons to India. Am J Epidemiol 84 (1966) 81-91
23. Taylor H. Trachoma grading: a new grading scheme. Rev Int Trach Pathol Ocul Trop Subtrop Santé Publique 64 (1987) 175-181
24. Bowman R., Faal H., Myatt M., et al. Longitudinal study of trachomatous trichiasis in the Gambia. Br J Ophthalmol 86 (2002) 339-343
25. Burton M., Bowman R., Faal H., et al. The long-term natural history of trachomatous trichiasis in the Gambia. Invest Ophthalmol Vis Sci 47 (2006) 847-852
26. Muñoz B., Aron J., Turner V., and West S. Incidence estimates of late stages of trachoma among women in a hyperendemic area of central Tanzania. Trop Med Int Health 2 (1997) 1030-1038
27. Muñoz B., Bobo L., Mkocha H., Lynch M., Hsieh Y., and West S. Incidence of trichiasis in a cohort of women with and without scarring. Int J Epidemiol 28 (1999) 1167-1171
28. Taylor H., Siler J., Mkocha H., Munoz B., and West S. The natural history of endemic trachoma: a longitudinal study. Am J Trop Med Hyg 46 (1992) 552-559
29. Bailey R., Osmond C., Mabey D., Whittle H., and Ward M. Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure. Int J Epidemiol 18 (1989) 944-951
30. Solomon A., Holland M., Burton M., et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet 362 (2003) 198-204
31. Conway D., Holland M., Campbell A., et al. HLA class I and II polymorphisms and trachomatous scarring in a Chlamydia trachomatis-endemic population. J Infect Dis 174 (1996) 643-646
32. Holland M., Conway D., Blanchard T., et al. Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population. Clin Exp Immunol 107 (1997) 44-49
33. Conway D., Holland M., Bailey R., et al. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect Immun 65 (1997) 1003-1006
34. Stephens R. The cellular paradigm of chlamydial pathogenesis. Trends Microbiol 11 (2003) 44-51
35. Ward M., Bailey R., Lesley A., Kajbaf M., Robertson J., and Mabey D. Persisting inapparent chlamydial infection in a trachoma endemic community in The Gambia. Scand J Infect Dis Suppl 69 (1990) 137-148
36. Mabey D., Bailey R., and Hutin Y. The epidemiology and pathogenesis of trachoma. Rev Med Microbiol 3 (1992) 112-119
37. Morrison R. New insights into a persistent problem-chlamydial infections. J Clin Invest 111 (2003) 1647-1649
38. Morrison R., and Caldwell H. Immunity to murine chlamydial genital infection. Infect Immun 70 (2002) 2741-2751
39. Beatty W., Morrison R., and Byrne G. Persistent Chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 58 (1994) 686-699
40. Bailey R., Holland M., Whittle H., and Mabey D. Subjects recovering from human ocular chlamydial infection have enhanced lymphoproliferative responses to chlamydial antigens compared with those of persistently diseased controls. Infect Immun 63 (1995) 389-392
41. Lansingh V., Weih L., Keeffe J., and Taylor H. Assessment of trachoma prevalence in a mobile population in Central Australia. Ophthalmic Epidemiol 8 (2001) 97-108
42. Schemann J., Sacko D., Banou A., et al. Cartography of trachoma in Mali: results of a national survey. Bull World Health Organ 76 (1998) 599-606 (in French).
43. Baral K., Osaki S., Shreshta B., et al. Reliability of clinical diagnosis in identifying infectious trachoma in a low-prevalence area of Nepal. Bull World Health Organ 77 (1999) 461-466
44. Hayes L., Bailey R., Mabey D., et al. Genotyping of Chlamydia trachomatis from a trachoma-endemic village in the Gambia by a nested polymerase chain reaction: identification of strain variants. J Infect Dis 166 (1992) 1173-1177
45. Burton M., Holland M., Faal N., et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci 44 (2003) 4215-4222
46. Solomon A., Peeling R., Foster A., and Mabey D. Diagnosis and assessment of trachoma. Clin Microbiol Rev 17 (2004) 982-1011
47. Miller K., Schmidt G., Melese M., et al. How reliable is the clinical exam in detecting ocular chlamydial infection?. Ophthalmic Epidemiol 11 (2004) 255-262
48. Burton M., Holland M., Jeffries D., Mabey D., and Bailey R. Conjunctival chlamydial 16S ribosomal RNA expression in trachoma: is chlamydial metabolic activity required for disease to develop?. Clin Infect Dis 42 (2006) 463-470
49. Melese M., Chidambaram J., Alemayehu W., et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 292 (2004) 721-725
50. Kasi P., Gilani A., Ahmad K., and Janjua N. Blinding trachoma: a disease of poverty. PLoS Med 1 (2004) e44
51. Anderson R., and May R. Infectious diseases of humans: dynamics and control (1992), Oxford University Press, Oxford
52. Madani M., Huguet P., Mariotti S., et al. Trachoma in Chad: results of an epidemiological survey. Santé 13 (2003) 9-15 (in French).
53. Dolin P., Faal H., Johnson G., Ajewole J., Mohamed A., and Lee P. Trachoma in The Gambia. Br J Ophthalmol 82 (1998) 930-933
54. Saal M., Schemann J., Saar B., et al. Trachoma in Senegal: results of a national survey. Méd Trop (Mars) 63 (2003) 53-59 (in French).
55. West S., Muñoz B., Turner V., Mmbaga B., and Taylor H. The epidemiology of trachoma in central Tanzania. Int J Epidemiol 20 (1991) 1088-1092
56. Courtright P. Contribution of sex-linked biology and gender roles to disparities with trachoma. Emerg Infect Dis 10 (2004) 2012-2016
57. Cumberland P., Hailu G., and Todd J. Active trachoma in children aged three to nine years in rural communities in Ethiopia: prevalence, indicators and risk factors. Trans R Soc Trop Med Hyg 99 (2005) 120-127
58. Werner G., and Sareen D. Trachoma in Punjab: a study of the prevalence and of mass treatment. Trop Geogr Med 29 (1977) 135-140
59. Regassa K., and Teshome T. Trachoma among adults in Damot Gale District, South Ethiopia. Ophthalmic Epidemiol 11 (2004) 9-16
60. Zerihun N. Trachoma in Jimma zone, south western Ethiopia. Trop Med Int Health 2 (1997) 1115-1121
61. West E., Muñoz B., Mkocha H., et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci 46 (2005) 83-87
62. Kumaresan J. Can blinding trachoma be eliminated by 20/20?. Eye 19 (2005) 1067-1073
63. Lietman T., Porco T., Dawson C., and Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy?. Nat Med 5 (1999) 572-576
64. Solomon A., Holland M., Alexander N., et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 351 (2004) 1962-1971
65. Michel C., Solomon A., Magbanua J., et al. Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: a comparative study. Lancet 367 (2006) 1585-1590
66. Taylor H., and Wright H. Dip-stick test for trachoma control programmes. Lancet 367 (2006) 1553-1554
67. Kuper H., Solomon A., Buchan J., Zondervan M., Foster A., and Mabey D. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis 3 (2003) 372-381